Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication

The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters... Opinion EDITORIAL The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication Marc De Hert, MD, PhD; Johan Detraux, MPsy Over the last 2 decades, there has been increasing wide- produced rapid-onset adverse changes in adiposity and insu- spread use of second-generation antipsychotic (SGA) medi- lin, with larger increases in those who used olanzapine com- cations in nonpsychotic pediatric populations in the United pared with those who used risperidone and aripiprazole. The 1-3 States and Europe. As the combined rates of overweight and obesity increased from ubiquity of SGA drugs in the baseline rate of 29.9% (43 of 144 participants) to 46.5% treatment plans for these (60 of 144 participants) in 12 weeks. These findings confirm Related article page 788 children and adolescents previous reports using conventional anthropometry, which grows, so does the controversy surrounding them. showed rapid-onset obesity and glucose dysregulation in Antipsychotic medications can induce cardiometabolic ab- children using SGA medications, as well as the greatest normalities (such as obesity, hyperglycemia, and dyslipid- weight gain and adverse changes in glucose metabolism in 2,5 emia) that are associated with an increased risk of cardiovas- those treated with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication

De Hert, Marc; Detraux, Johan
JAMA Psychiatry , Volume 75 (8) – Aug 13, 2018
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/the-urgent-need-for-optimal-monitoring-of-metabolic-adverse-effects-in-h6orthTpFY

References (16)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2018.1080
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication Marc De Hert, MD, PhD; Johan Detraux, MPsy Over the last 2 decades, there has been increasing wide- produced rapid-onset adverse changes in adiposity and insu- spread use of second-generation antipsychotic (SGA) medi- lin, with larger increases in those who used olanzapine com- cations in nonpsychotic pediatric populations in the United pared with those who used risperidone and aripiprazole. The 1-3 States and Europe. As the combined rates of overweight and obesity increased from ubiquity of SGA drugs in the baseline rate of 29.9% (43 of 144 participants) to 46.5% treatment plans for these (60 of 144 participants) in 12 weeks. These findings confirm Related article page 788 children and adolescents previous reports using conventional anthropometry, which grows, so does the controversy surrounding them. showed rapid-onset obesity and glucose dysregulation in Antipsychotic medications can induce cardiometabolic ab- children using SGA medications, as well as the greatest normalities (such as obesity, hyperglycemia, and dyslipid- weight gain and adverse changes in glucose metabolism in 2,5 emia) that are associated with an increased risk of cardiovas- those treated with

Journal

JAMA Psychiatry – American Medical Association

Published: Aug 13, 2018

There are no references for this article.